TESARO Bio Netherlands

Company snapshot

TESARO Bio Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Ovarian Neoplasms, Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer, Recurrent or primary advanced (Stage III or IV) endometrial cancer, Homologous recombination deficiency advanced ovarian cancer. NovaPharmaNews links 6 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (3), phase 1 (2), phase 2 (1).

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for TESARO Bio Netherlands. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for TESARO Bio Netherlands.

1. Jun 8, 2026 Clinical update

   PR-30-5017-C — Phase 3

2. Jun 8, 2026 Clinical update

   AMBER — Phase 1

3. Jun 8, 2026 Clinical update

   4010-01-001 — Phase 1

4. Jun 8, 2026 Clinical update

   213357 — Phase 2

5. Jun 8, 2026 Clinical update

   213350/3000-03-005 — Phase 3

View all clinical trial activity →

• What is TESARO Bio Netherlands?

  TESARO Bio Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Ovarian Neoplasms, Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer, Recurrent or primary advanced (Stage III or IV) endometrial cancer, Homologous recombination defici

• Is TESARO Bio Netherlands publicly traded?

  TESARO Bio Netherlands appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does TESARO Bio Netherlands develop or market?

  We link 23 drug profile(s) where TESARO Bio Netherlands is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tesaro-bio-netherlands-b-v#company-drugs.

• What are the latest developments for TESARO Bio Netherlands?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does TESARO Bio Netherlands focus on?

  TESARO Bio Netherlands focuses on Ovarian Neoplasms, Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer, Recurrent or primary advanced (Stage III or IV) endometrial cancer based on our analysis of their pipeline programs and drug development activities.